AU2013274003B2 - Compositions and methods for transmucosal absorption - Google Patents

Compositions and methods for transmucosal absorption Download PDF

Info

Publication number
AU2013274003B2
AU2013274003B2 AU2013274003A AU2013274003A AU2013274003B2 AU 2013274003 B2 AU2013274003 B2 AU 2013274003B2 AU 2013274003 A AU2013274003 A AU 2013274003A AU 2013274003 A AU2013274003 A AU 2013274003A AU 2013274003 B2 AU2013274003 B2 AU 2013274003B2
Authority
AU
Australia
Prior art keywords
equal
administration
hours
composition
cyclobenzaprine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013274003A
Other languages
English (en)
Other versions
AU2013274003A1 (en
Inventor
Harry Brittain
Seth Lederman
Giorgio Reiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Holdings Ltd
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Publication of AU2013274003A1 publication Critical patent/AU2013274003A1/en
Application granted granted Critical
Publication of AU2013274003B2 publication Critical patent/AU2013274003B2/en
Priority to AU2018241128A priority Critical patent/AU2018241128B2/en
Assigned to TONIX PHARMA HOLDINGS LIMITED reassignment TONIX PHARMA HOLDINGS LIMITED Request for Assignment Assignors: Tonix Pharmaceuticals, Inc.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2013274003A 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption Active AU2013274003B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018241128A AU2018241128B2 (en) 2012-06-15 2018-10-04 Compositions and Methods for Transmucosal Absorption

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261660593P 2012-06-15 2012-06-15
US61/660,593 2012-06-15
US201261667774P 2012-07-03 2012-07-03
US61/667,774 2012-07-03
US201261725402P 2012-11-12 2012-11-12
US61/725,402 2012-11-12
US201361792900P 2013-03-15 2013-03-15
US61/792,900 2013-03-15
PCT/US2013/046023 WO2013188847A1 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018241128A Division AU2018241128B2 (en) 2012-06-15 2018-10-04 Compositions and Methods for Transmucosal Absorption

Publications (2)

Publication Number Publication Date
AU2013274003A1 AU2013274003A1 (en) 2015-02-05
AU2013274003B2 true AU2013274003B2 (en) 2018-07-05

Family

ID=49758769

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013274003A Active AU2013274003B2 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption
AU2018241128A Active AU2018241128B2 (en) 2012-06-15 2018-10-04 Compositions and Methods for Transmucosal Absorption

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018241128A Active AU2018241128B2 (en) 2012-06-15 2018-10-04 Compositions and Methods for Transmucosal Absorption

Country Status (26)

Country Link
US (1) US20140171515A1 (enExample)
EP (1) EP2861223B1 (enExample)
JP (5) JP6259452B2 (enExample)
CN (2) CN111388430A (enExample)
AR (1) AR092330A1 (enExample)
AU (2) AU2013274003B2 (enExample)
BR (1) BR112014031394B1 (enExample)
CA (2) CA2876902C (enExample)
DK (1) DK2861223T3 (enExample)
ES (1) ES2929133T3 (enExample)
HR (1) HRP20221325T1 (enExample)
HU (1) HUE060175T2 (enExample)
IL (1) IL236268B (enExample)
LT (1) LT2861223T (enExample)
MX (2) MX2021005317A (enExample)
MY (1) MY194495A (enExample)
NZ (2) NZ631144A (enExample)
PL (1) PL2861223T3 (enExample)
PT (1) PT2861223T (enExample)
RS (1) RS63822B1 (enExample)
SG (2) SG11201408318RA (enExample)
SI (1) SI2861223T1 (enExample)
SM (1) SMT202200436T1 (enExample)
TW (3) TWI683660B (enExample)
WO (1) WO2013188847A1 (enExample)
ZA (1) ZA201500288B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037281T2 (hu) 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ES2769879T3 (es) 2013-03-15 2020-06-29 Tonix Pharma Holdings Ltd Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol
CN107072968B (zh) 2014-09-18 2021-01-12 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
CN108024976A (zh) * 2015-07-15 2018-05-11 特兰埃克斯公司 阿米替林用于阻断大脑半通道的用途和用于增强其体内作用的方法
US12337063B2 (en) * 2016-09-02 2025-06-24 University Of Sharjah Formulation for atropine sulfate rapidly-disintegrating sublingual tablets
WO2019014651A1 (en) 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. ANALOGUES OF CYCLOBENZAPRINE AND AMITRYPTILENE
CN107496355B (zh) * 2017-08-24 2021-04-30 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下喷雾剂及其制备方法
CN107519142B (zh) * 2017-08-24 2021-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下片及其制备方法
IL275144B2 (en) * 2017-12-08 2024-12-01 Hoffmann La Roche Pharmaceutical formulation
MX2020006140A (es) 2017-12-11 2020-08-13 Tonix Pharma Holdings Ltd Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
CN108721240A (zh) * 2018-06-08 2018-11-02 华益药业科技(安徽)有限公司 一种25mg阿米替林薄膜包衣片处方和工艺规程
JP7691739B2 (ja) * 2018-08-20 2025-06-12 トニックス ファーマ ホールディングス リミテッド 急性ストレス障害および外傷後ストレス障害を処置する方法
US20220339124A1 (en) * 2019-09-30 2022-10-27 Cadila Healthcare Limited Intranasal pharmaceutical compositions of cyclobenzaprine
US20210315841A1 (en) * 2020-04-08 2021-10-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
MX2023005899A (es) 2020-11-20 2023-08-16 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol.
MX2023006720A (es) 2020-12-07 2023-08-18 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para fibromialgia.
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
EP4412602A1 (en) 2021-10-06 2024-08-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
JP2025519847A (ja) 2022-06-21 2025-06-26 トニックス ファーマシューティカルズ ホールディング コーポレイション （ＳＡＲＳ）－ＣｏＶ－２感染症の急性期後後遺症（ＰＡＳＣ）のためのシクロベンザプリン処置
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
DE69904465T2 (de) * 1998-05-14 2003-10-02 Alza Corp., Mountain View Therapie von depressionen
AR025110A1 (es) 1999-08-13 2002-11-06 Vela Pharmaceuticals Inc Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina
BR0013122A (pt) 1999-08-13 2002-04-30 Vela Pharmaceuticals Inc Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
EP1596824A4 (en) * 2003-02-04 2011-11-23 Chrysalis Tech Inc AEROSOL FORMULATIONS AND AEROSOL DISTRIBUTION OF BUSPIRONE, BUPRENORPHINE, TRIAZOLAM, CYCLOBENZAPRINE AND ZOLPIDEM
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP2009079060A (ja) * 2008-10-15 2009-04-16 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
HUE037281T2 (hu) * 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
ES2769879T3 (es) * 2013-03-15 2020-06-29 Tonix Pharma Holdings Ltd Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same

Also Published As

Publication number Publication date
TW201842903A (zh) 2018-12-16
CA3118913A1 (en) 2013-12-19
TWI642429B (zh) 2018-12-01
CA2876902A1 (en) 2013-12-19
ES2929133T3 (es) 2022-11-25
JP2021138765A (ja) 2021-09-16
ZA201500288B (en) 2022-05-25
EP2861223B1 (en) 2022-08-03
JP2017222726A (ja) 2017-12-21
SMT202200436T1 (it) 2023-01-13
TW201408281A (zh) 2014-03-01
JP6259452B2 (ja) 2018-01-10
AU2013274003A1 (en) 2015-02-05
LT2861223T (lt) 2022-12-12
EP2861223A1 (en) 2015-04-22
JP2015519404A (ja) 2015-07-09
BR112014031394B1 (pt) 2022-10-18
PL2861223T3 (pl) 2022-12-12
TW201731494A (zh) 2017-09-16
NZ631144A (en) 2016-12-23
TWI683660B (zh) 2020-02-01
MX382516B (es) 2025-03-13
NZ726488A (en) 2018-10-26
EP2861223A4 (en) 2016-01-27
JP2019123757A (ja) 2019-07-25
CA2876902C (en) 2021-07-13
SG11201408318RA (en) 2015-01-29
AR092330A1 (es) 2015-04-15
MY194495A (en) 2022-11-30
DK2861223T3 (da) 2022-11-07
JP2024032964A (ja) 2024-03-12
IL236268B (en) 2022-03-01
HRP20221325T1 (hr) 2022-12-23
AU2018241128B2 (en) 2020-05-21
CA3118913C (en) 2024-04-30
SG10201605407TA (en) 2016-08-30
HUE060175T2 (hu) 2023-02-28
AU2018241128A1 (en) 2018-10-25
WO2013188847A1 (en) 2013-12-19
IL236268A0 (en) 2015-02-26
RS63822B1 (sr) 2023-01-31
SI2861223T1 (sl) 2023-01-31
MX2014015436A (es) 2015-07-14
HK1209361A1 (en) 2016-04-01
MX2021005317A (es) 2022-12-16
US20140171515A1 (en) 2014-06-19
PT2861223T (pt) 2022-11-07
BR112014031394A2 (pt) 2017-06-27
CN111388430A (zh) 2020-07-10
CN104684550A (zh) 2015-06-03
TWI590820B (zh) 2017-07-11
BR112014031394A8 (pt) 2021-11-03
WO2013188847A8 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
AU2018241128B2 (en) Compositions and Methods for Transmucosal Absorption
US11737991B2 (en) Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
RS53995B1 (sr) Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
WO2002030400A1 (fr) Preparations solides
HK1209361B (en) Compositions and methods for transmucosal absorption
WO2014145045A1 (en) Compositions and methods for transmucosal absorption
HK40029464A (en) Compositions and methods for transmucosal absorption

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 23 NOV 2016

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TONIX PHARMA HOLDINGS LIMITED

Free format text: FORMER OWNER(S): TONIX PHARMACEUTICALS, INC.